Status:
UNKNOWN
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Hypoactive Sexual Desire Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Hypoactive Sexual Desire Disorder (HSDD) is a common syndrome characterized by low sexual desire causing marked distress. The involvement of DHEA in sexual function is unknown, however, DHEA treatment...
Detailed Description
Hypoactive Sexual Desire Disorder (HSDD) is a very common syndrome in adult women and men, characterized by a severe deficiency in the desire for sexual activity, causing marked distress. There is som...
Eligibility Criteria
Inclusion
- Woman participating in the research will be in the menopausal phase or after it (above a year in postmenopause)aged 65 and below. Man age range will be 18 - 65.
Exclusion
- Individuals suffering from a significant systemic illness, hormonal illness, alcoholism, drug abuse, major depression, "Mano/matroagia" or hypogonadism. Additionally, individuals treated with androgens, antidepressant or any other medication which may cause a disorder in sexual desire.
- Man diagnosed as suffering from prostate carcinoma, BHP or will show PSA levels above 2.5 will not be included.
- Woman treated with HRT or suffering from any of the following diseases will not be included: breast carcinoma, ovarian or uterus cancer or with a first grade family history of one of the mentioned.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00916396
Start Date
June 1 2005
End Date
December 1 2011
Last Update
December 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tel Aviv Aviv Medical Center
Tel Aviv, Israel